
<div id="jpedal" style="overflow: hidden; position: relative; width: 909px; height: 1212px;">
<style type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position:absolute;
	white-space:nowrap;
	overflow:visible;
}
</style>
<style type="text/css" >

#t1_1{left:69px;top:124px;word-spacing:6.5px;}
#t2_1{left:69px;top:146px;letter-spacing:-0.2px;word-spacing:8.8px;}
#t3_1{left:69px;top:183px;word-spacing:10.1px;}
#t4_1{left:69px;top:231px;letter-spacing:-0.5px;word-spacing:5.9px;}
#t5_1{left:150px;top:229px;}
#t6_1{left:163px;top:231px;letter-spacing:-0.1px;word-spacing:4.6px;}
#t7_1{left:250px;top:229px;}
#t8_1{left:263px;top:231px;word-spacing:4.4px;}
#t9_1{left:323px;top:229px;}
#ta_1{left:328px;top:231px;letter-spacing:0.1px;word-spacing:4.6px;}
#tb_1{left:384px;top:229px;}
#tc_1{left:389px;top:231px;word-spacing:4.7px;}
#td_1{left:464px;top:229px;}
#te_1{left:474px;top:231px;word-spacing:4.7px;}
#tf_1{left:551px;top:229px;}
#tg_1{left:87px;top:277px;word-spacing:4.7px;}
#th_1{left:87px;top:294px;word-spacing:4.7px;}
#ti_1{left:87px;top:310px;word-spacing:4.7px;}
#tj_1{left:87px;top:327px;word-spacing:1.3px;}
#tk_1{left:87px;top:344px;word-spacing:1.3px;}
#tl_1{left:87px;top:361px;word-spacing:4.7px;}
#tm_1{left:87px;top:377px;word-spacing:2.1px;}
#tn_1{left:712px;top:376px;}
#to_1{left:722px;top:376px;}
#tp_1{left:727px;top:377px;word-spacing:3px;}
#tq_1{left:87px;top:394px;word-spacing:-4.4px;}
#tr_1{left:121px;top:393px;}
#ts_1{left:131px;top:393px;}
#tt_1{left:141px;top:394px;word-spacing:0.9px;}
#tu_1{left:320px;top:393px;}
#tv_1{left:330px;top:393px;}
#tw_1{left:335px;top:394px;word-spacing:4.7px;}
#tx_1{left:87px;top:411px;word-spacing:3.1px;}
#ty_1{left:551px;top:409px;}
#tz_1{left:560px;top:409px;}
#t10_1{left:566px;top:411px;}
#t11_1{left:573px;top:411px;}
#t12_1{left:582px;top:411px;}
#t13_1{left:595px;top:411px;word-spacing:4.7px;}
#t14_1{left:87px;top:428px;word-spacing:3.1px;}
#t15_1{left:489px;top:426px;}
#t16_1{left:498px;top:426px;}
#t17_1{left:504px;top:428px;}
#t18_1{left:511px;top:428px;}
#t19_1{left:520px;top:428px;}
#t1a_1{left:533px;top:428px;word-spacing:4.7px;}
#t1b_1{left:87px;top:444px;word-spacing:-0.3px;}
#t1c_1{left:87px;top:461px;word-spacing:4.7px;}
#t1d_1{left:87px;top:495px;word-spacing:4.8px;}
#t1e_1{left:340px;top:495px;}
#t1f_1{left:380px;top:495px;}
#t1g_1{left:404px;top:495px;word-spacing:4.7px;}
#t1h_1{left:87px;top:520px;}
#t1i_1{left:158px;top:520px;word-spacing:4.8px;}
#t1j_1{left:69px;top:600px;}
#t1k_1{left:69px;top:618px;word-spacing:8.8px;}
#t1l_1{left:69px;top:633px;}
#t1m_1{left:83px;top:633px;word-spacing:0.1px;}
#t1n_1{left:310px;top:633px;}
#t1o_1{left:324px;top:633px;word-spacing:0.1px;}
#t1p_1{left:395px;top:632px;}
#t1q_1{left:404px;top:633px;}
#t1r_1{left:69px;top:648px;word-spacing:7.4px;}
#t1s_1{left:69px;top:664px;letter-spacing:0.8px;word-spacing:17.7px;}
#t1t_1{left:69px;top:679px;letter-spacing:0.9px;word-spacing:12.1px;}
#t1u_1{left:136px;top:679px;}
#t1v_1{left:150px;top:679px;letter-spacing:0.9px;word-spacing:12.1px;}
#t1w_1{left:69px;top:694px;letter-spacing:0.9px;word-spacing:20.1px;}
#t1x_1{left:300px;top:692px;}
#t1y_1{left:314px;top:694px;letter-spacing:1px;word-spacing:20px;}
#t1z_1{left:69px;top:709px;letter-spacing:0.9px;word-spacing:20.8px;}
#t20_1{left:69px;top:724px;letter-spacing:1px;word-spacing:13.8px;}
#t21_1{left:69px;top:740px;letter-spacing:1px;word-spacing:19.6px;}
#t22_1{left:69px;top:755px;letter-spacing:0.9px;word-spacing:19.5px;}
#t23_1{left:69px;top:770px;letter-spacing:0.9px;word-spacing:9.3px;}
#t24_1{left:69px;top:785px;letter-spacing:1px;word-spacing:14.7px;}
#t25_1{left:69px;top:801px;letter-spacing:1px;word-spacing:4.6px;}
#t26_1{left:278px;top:799px;letter-spacing:1.1px;}
#t27_1{left:83px;top:816px;word-spacing:10.6px;}
#t28_1{left:69px;top:831px;word-spacing:9.9px;}
#t29_1{left:69px;top:846px;word-spacing:6.6px;}
#t2a_1{left:69px;top:861px;word-spacing:9.7px;}
#t2b_1{left:393px;top:860px;}
#t2c_1{left:404px;top:861px;word-spacing:9.3px;}
#t2d_1{left:69px;top:877px;word-spacing:0.5px;}
#t2e_1{left:69px;top:892px;word-spacing:-0.6px;}
#t2f_1{left:271px;top:892px;word-spacing:-0.7px;}
#t2g_1{left:312px;top:892px;word-spacing:-0.6px;}
#t2h_1{left:69px;top:907px;letter-spacing:-0.9px;word-spacing:1.5px;}
#t2i_1{left:69px;top:922px;}
#t2j_1{left:139px;top:921px;}
#t2k_1{left:149px;top:922px;word-spacing:3.1px;}
#t2l_1{left:69px;top:937px;word-spacing:5.3px;}
#t2m_1{left:69px;top:953px;word-spacing:6.9px;}
#t2n_1{left:69px;top:968px;word-spacing:6.3px;}
#t2o_1{left:69px;top:983px;word-spacing:19.2px;}
#t2p_1{left:69px;top:998px;word-spacing:4.2px;}
#t2q_1{left:69px;top:1014px;word-spacing:4.6px;}
#t2r_1{left:489px;top:600px;word-spacing:7px;}
#t2s_1{left:476px;top:615px;word-spacing:-0.3px;}
#t2t_1{left:476px;top:630px;word-spacing:19.1px;}
#t2u_1{left:476px;top:646px;word-spacing:-0.2px;}
#t2v_1{left:574px;top:644px;}
#t2w_1{left:598px;top:646px;word-spacing:-0.2px;}
#t2x_1{left:476px;top:661px;word-spacing:-0.2px;}
#t2y_1{left:476px;top:677px;word-spacing:7.5px;}
#t2z_1{left:476px;top:692px;word-spacing:25.7px;}
#t30_1{left:476px;top:708px;word-spacing:5.3px;}
#t31_1{left:623px;top:706px;letter-spacing:0.1px;}
#t32_1{left:654px;top:708px;word-spacing:5.3px;}
#t33_1{left:476px;top:724px;word-spacing:2.5px;}
#t34_1{left:476px;top:739px;word-spacing:22.4px;}
#t35_1{left:476px;top:755px;word-spacing:17px;}
#t36_1{left:476px;top:770px;word-spacing:2.9px;}
#t37_1{left:476px;top:786px;word-spacing:2.2px;}
#t38_1{left:756px;top:784px;}
#t39_1{left:783px;top:786px;word-spacing:2.2px;}
#t3a_1{left:476px;top:801px;word-spacing:26.6px;}
#t3b_1{left:476px;top:817px;word-spacing:15.8px;}
#t3c_1{left:476px;top:832px;word-spacing:13.8px;}
#t3d_1{left:476px;top:848px;word-spacing:4.6px;}
#t3e_1{left:722px;top:846px;}
#t3f_1{left:489px;top:863px;word-spacing:16.4px;}
#t3g_1{left:476px;top:878px;word-spacing:6.4px;}
#t3h_1{left:476px;top:893px;word-spacing:5.2px;}
#t3i_1{left:476px;top:909px;word-spacing:-0.6px;}
#t3j_1{left:476px;top:924px;word-spacing:6.6px;}
#t3k_1{left:630px;top:924px;word-spacing:6.6px;}
#t3l_1{left:671px;top:924px;}
#t3m_1{left:673px;top:922px;}
#t3n_1{left:689px;top:924px;word-spacing:6.7px;}
#t3o_1{left:476px;top:939px;word-spacing:10.9px;}
#t3p_1{left:476px;top:954px;word-spacing:11px;}
#t3q_1{left:476px;top:969px;word-spacing:9.9px;}
#t3r_1{left:476px;top:985px;word-spacing:3.5px;}
#t3s_1{left:476px;top:1000px;word-spacing:8.9px;}
#t3t_1{left:476px;top:1015px;word-spacing:4.6px;}
#t3u_1{left:69px;top:1053px;}
#t3v_1{left:73px;top:1054px;word-spacing:2.2px;}
#t3w_1{left:417px;top:1053px;}
#t3x_1{left:421px;top:1054px;word-spacing:2px;}
#t3y_1{left:648px;top:1053px;}
#t3z_1{left:652px;top:1054px;letter-spacing:0.1px;word-spacing:1.8px;}
#t40_1{left:69px;top:1068px;word-spacing:3.8px;}
#t41_1{left:69px;top:1081px;word-spacing:3.8px;}
#t42_1{left:69px;top:1094px;}
#t43_1{left:73px;top:1095px;word-spacing:3.8px;}
#t44_1{left:69px;top:1109px;word-spacing:3.7px;}
#t45_1{left:129px;top:34px;letter-spacing:0.1px;word-spacing:3.8px;}
#t46_1{left:112px;top:49px;}
#t47_1{left:125px;top:49px;word-spacing:4.4px;}
#t48_1{left:297px;top:49px;word-spacing:4.3px;}
#t49_1{left:338px;top:71px;}

.s15_1{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae811;
	color: rgb(35,31,32);
}

.s17_1{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCNGI-AdvOT3b30f6db-B1;
	color: rgb(35,31,32);
}

.s3_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNFE-AdvTT6780a46b1;
	color: rgb(35,31,32);
}

.s13_1{
	FONT-SIZE: 28.4px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae811;
	color: rgb(35,31,32);
}

.s5_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae811;
	color: rgb(35,31,32);
}

.s1_1{
	FONT-SIZE: 73.1px;
	FONT-FAMILY: JBCNFC-AdvTT5afe5d37-B1;
	color: rgb(35,31,32);
}

.s10_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGI-AdvOT3b30f6db-B1;
	color: rgb(35,31,32);
}

.s11_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGJ-AdvEls-ent41;
	color: rgb(35,31,32);
}

.s8_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGH-AdvOT65f8a23b-I1;
	color: rgb(35,31,32);
}

.s9_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGG-AdvP4C4E741;
	color: rgb(35,31,32);
}

.s12_1{
	FONT-SIZE: 54.8px;
	FONT-FAMILY: JBCNGK-AdvPi11;
	color: rgb(35,31,32);
}

.s14_1{
	FONT-SIZE: 42.6px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae811;
	color: rgb(35,31,32);
}

.s16_1{
	FONT-SIZE: 48.7px;
	FONT-FAMILY: JBCOAH-AdvTA421;
	color: rgb(35,31,32);
}

.s6_1{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNGG-AdvP4C4E741;
	color: rgb(35,31,32);
}

.s4_1{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNFE-AdvTT6780a46b1;
	color: rgb(35,31,32);
}

.s7_1{
	FONT-SIZE: 36.5px;
	FONT-FAMILY: JBCNFF-AdvOT46dcae811;
	color: rgb(35,31,32);
}

.s2_1{
	FONT-SIZE: 118.7px;
	FONT-FAMILY: JBCNFD-AdvTT5843c5711;
	color: rgb(35,31,32);
}

.v1_1{
	-webkit-transform: scale(0.281, 0.25);
	-ms-transform: scale(0.281, 0.25);
	-moz-transform: scale(0.281, 0.25);
	-o-transform: scale(0.281, 0.25);
}

.v2_1{
	-webkit-transform: scale(0.224, 0.25);
	-ms-transform: scale(0.224, 0.25);
	-moz-transform: scale(0.224, 0.25);
	-o-transform: scale(0.224, 0.25);
}

#form1_1{	border-style:none;	z-index:2;	position: absolute;	left:139px;	top:918px;	width:6px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_2{	border-style:none;	z-index:2;	position: absolute;	left:300px;	top:689px;	width:6px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_3{	border-style:none;	z-index:2;	position: absolute;	left:393px;	top:857px;	width:6px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_4{	border-style:none;	z-index:2;	position: absolute;	left:394px;	top:628px;	width:8px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_5{	border-style:none;	z-index:2;	position: absolute;	left:721px;	top:844px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_6{	border-style:none;	z-index:2;	position: absolute;	left:672px;	top:920px;	width:12px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_7{	border-style:none;	z-index:2;	position: absolute;	left:277px;	top:796px;	width:19px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_8{	border-style:none;	z-index:2;	position: absolute;	left:573px;	top:642px;	width:23px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_9{	border-style:none;	z-index:2;	position: absolute;	left:755px;	top:781px;	width:25px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}
#form1_10{	border-style:none;	z-index:2;	position: absolute;	left:622px;	top:704px;	width:28px;	height:14px;	text-align:left;	background: transparent;	font:normal 10px Arial, Helvetica, sans-serif;}
#form1_11{	border-style:none;	z-index:2;	position: absolute;	left:101px;	top:1082px;	width:83px;	height:12px;	text-align:left;	background: transparent;	font:normal 9px Arial, Helvetica, sans-serif;}
#form1_12{	border-style:none;	z-index:2;	position: absolute;	left:336px;	top:72px;	width:113px;	height:14px;	text-align:left;	background: transparent;	font:normal 10px Arial, Helvetica, sans-serif;}
#form1_13{	border-style:none;	z-index:2;	position: absolute;	left:466px;	top:497px;	width:112px;	height:15px;	text-align:left;	background: transparent;	font:normal 12px Arial, Helvetica, sans-serif;}

</style>
<style id="fonts1" type="text/css" >

@font-face {
	font-family: JBCOAH-AdvTA421;
	src: url("1/fonts/JBCOAH-AdvTA42.woff") format("woff");
}

@font-face {
	font-family: JBCNGG-AdvP4C4E741;
	src: url("1/fonts/JBCNGG-AdvP4C4E74.woff") format("woff");
}

@font-face {
	font-family: JBCNFD-AdvTT5843c5711;
	src: url("1/fonts/JBCNFD-AdvTT5843c571.woff") format("woff");
}

@font-face {
	font-family: JBCNFF-AdvOT46dcae811;
	src: url("1/fonts/JBCNFF-AdvOT46dcae81.woff") format("woff");
}

@font-face {
	font-family: JBCNGJ-AdvEls-ent41;
	src: url("1/fonts/JBCNGJ-AdvEls-ent4.woff") format("woff");
}

@font-face {
	font-family: JBCNFC-AdvTT5afe5d37-B1;
	src: url("1/fonts/JBCNFC-AdvTT5afe5d37-B.woff") format("woff");
}

@font-face {
	font-family: JBCNGK-AdvPi11;
	src: url("1/fonts/JBCNGK-AdvPi1.woff") format("woff");
}

@font-face {
	font-family: JBCNGI-AdvOT3b30f6db-B1;
	src: url("1/fonts/JBCNGI-AdvOT3b30f6db-B.woff") format("woff");
}

@font-face {
	font-family: JBCNFE-AdvTT6780a46b1;
	src: url("1/fonts/JBCNFE-AdvTT6780a46b.woff") format("woff");
}

@font-face {
	font-family: JBCNGH-AdvOT65f8a23b-I1;
	src: url("1/fonts/JBCNGH-AdvOT65f8a23b-I.woff") format("woff");
}

</style>
<div id="t1_1" class="t s1_1">ORIGINAL ARTICLE</div>
<div id="t2_1" class="t s2_1">Testosterone replacement therapy in the setting of prostate cancer</div>
<div id="t3_1" class="t s2_1">treated with radiation</div>
<div id="t4_1" class="t s3_1">AW Pastuszak</div>
<div id="t5_1" class="t v1_1 s4_1">1,4</div>
<div id="t6_1" class="t s3_1">, AM Pearlman</div>
<div id="t7_1" class="t v1_1 s4_1">2,4</div>
<div id="t8_1" class="t s3_1">, G Godoy</div>
<div id="t9_1" class="t v1_1 s4_1">1</div>
<div id="ta_1" class="t s3_1">, BJ Miles</div>
<div id="tb_1" class="t v1_1 s4_1">3</div>
<div id="tc_1" class="t s3_1">, LI Lipshultz</div>
<div id="td_1" class="t v1_1 s4_1">1</div>
<div id="te_1" class="t s3_1">and M Khera</div>
<div id="tf_1" class="t v1_1 s4_1">1</div>
<div id="tg_1" class="t s5_1">A lack of consensus and few data support testosterone replacement therapy (TRT) in hypogonadal men who have been treated</div>
<div id="th_1" class="t s5_1">for prostate cancer (CaP), particularly those who have received radiation therapy. We performed retrospective review of 13</div>
<div id="ti_1" class="t s5_1">hypogonadal men with CaP, treated with brachytherapy or external beam radiotherapy who were subsequently treated with</div>
<div id="tj_1" class="t s5_1">testosterone (T) between 2006 and 2011. Serum T, free T (FT), estrogen (E), sex hormone-binding globulin (SHBG), prostate-speci±c</div>
<div id="tk_1" class="t s5_1">antigen (PSA), hemoglobin (Hgb) and hematocrit (Hct) values were evaluated approximately every 3 months after TRT initiation up</div>
<div id="tl_1" class="t s5_1">to 67 months of follow-up. Prostate biopsies demonstrated four men with Gleason (Gl) 6, 7 with Gl 7 and 2 with Gl 8 disease.</div>
<div id="tm_1" class="t s5_1">Median (interquartile range) age at TRT initiation was 68.0 (62.0–77.0) years, initial T 178.0 (88.0–263.5) ng dl</div>
<div id="tn_1" class="t v1_1 s6_1">±</div>
<div id="to_1" class="t v1_1 s7_1">1</div>
<div id="tp_1" class="t s5_1">, FT 10.1 (5.7–15.0)</div>
<div id="tq_1" class="t s5_1">pg ml</div>
<div id="tr_1" class="t v1_1 s6_1">±</div>
<div id="ts_1" class="t v1_1 s7_1">1</div>
<div id="tt_1" class="t s5_1">and PSA 0.30 (0.06–0.95) ng ml</div>
<div id="tu_1" class="t v1_1 s6_1">±</div>
<div id="tv_1" class="t v1_1 s7_1">1</div>
<div id="tw_1" class="t s5_1">. Median follow-up after TRT initiation was 29.7 months (range 2.3–67.3 months).</div>
<div id="tx_1" class="t s5_1">At median follow-up, a signi±cant increase in mean T (368.0 (281.3–591.0) ng dl</div>
<div id="ty_1" class="t v1_1 s6_1">±</div>
<div id="tz_1" class="t v1_1 s7_1">1</div>
<div id="t10_1" class="t s5_1">,</div>
<div id="t11_1" class="t s8_1">P</div>
<div id="t12_1" class="t s9_1">¼</div>
<div id="t13_1" class="t s5_1">0.012) and SHBG were observed, with no</div>
<div id="t14_1" class="t s5_1">signi±cant increases in Hgb, Hct, E, FT, or PSA (0.66 (0.16–1.35) ng ml</div>
<div id="t15_1" class="t v1_1 s6_1">±</div>
<div id="t16_1" class="t v1_1 s7_1">1</div>
<div id="t17_1" class="t s5_1">,</div>
<div id="t18_1" class="t s8_1">P</div>
<div id="t19_1" class="t s9_1">¼</div>
<div id="t1a_1" class="t s5_1">0.345). No signi±cant increases in PSA or CaP</div>
<div id="t1b_1" class="t s5_1">recurrences were observed at any follow-up interval. TRT in the setting of CaP after treatment with radiation therapy results in a rise</div>
<div id="t1c_1" class="t s5_1">in serum T levels and improvement in hypogonadal symptoms without evidence of CaP recurrence or progression.</div>
<div id="t1d_1" class="t s8_1">International Journal of Impotence Research</div>
<div id="t1e_1" class="t s5_1">(2013)</div>
<div id="t1f_1" class="t s10_1">25,</div>
<div id="t1g_1" class="t s5_1">24–28; doi:10.1038/ijir.2012.29; published online 13 September 2012</div>
<div id="t1h_1" class="t s10_1">Keywords:</div>
<div id="t1i_1" class="t s5_1">hypogonadism; prostate cancer; radiation therapy; testosterone replacement</div>
<div id="t1j_1" class="t s10_1">INTRODUCTION</div>
<div id="t1k_1" class="t s5_1">Late-onset hypogonadism (LOH) is present in up to 7% of men</div>
<div id="t1l_1" class="t s11_1">o</div>
<div id="t1m_1" class="t s5_1">70 years old and in up to 18.4% of men</div>
<div id="t1n_1" class="t s12_1">4</div>
<div id="t1o_1" class="t s5_1">70 years old.</div>
<div id="t1p_1" class="t v1_1 s7_1">1</div>
<div id="t1q_1" class="t s5_1">Though</div>
<div id="t1r_1" class="t s5_1">men over the age of 65 years currently account for 5.6% of the</div>
<div id="t1s_1" class="t s5_1">US population, this age group is growing 2–3 times faster</div>
<div id="t1t_1" class="t s5_1">than men</div>
<div id="t1u_1" class="t s11_1">o</div>
<div id="t1v_1" class="t s5_1">65 years old, suggesting that the prevalence of</div>
<div id="t1w_1" class="t s5_1">LOH will only continue to increase.</div>
<div id="t1x_1" class="t v1_1 s7_1">2</div>
<div id="t1y_1" class="t s5_1">Characterized by low</div>
<div id="t1z_1" class="t s5_1">serum testosterone (T), as well as symptoms of androgen</div>
<div id="t20_1" class="t s5_1">de±ciency, which include loss of libido, erectile dysfunction,</div>
<div id="t21_1" class="t s5_1">depression, lethargy, concentration dif±culties, sleep distur-</div>
<div id="t22_1" class="t s5_1">bance, osteoporosis and loss of muscle strength, LOH has</div>
<div id="t23_1" class="t s5_1">widespread implications on men’s health and has been asso-</div>
<div id="t24_1" class="t s5_1">ciated with cardiovascular disease, insulin resistance, type II</div>
<div id="t25_1" class="t s5_1">diabetes and metabolic syndrome.</div>
<div id="t26_1" class="t v1_1 s7_1">3–6</div>
<div id="t27_1" class="t s5_1">Treatment with testosterone replacement therapy (TRT) ame-</div>
<div id="t28_1" class="t s5_1">liorates the symptoms of hypogonadism, but is controversial in</div>
<div id="t29_1" class="t s5_1">the setting of prostate cancer (CaP) due to the belief that T can</div>
<div id="t2a_1" class="t s5_1">stimulate its growth. A study by Huggins and Hudges</div>
<div id="t2b_1" class="t v1_1 s7_1">7</div>
<div id="t2c_1" class="t s5_1">in 1941</div>
<div id="t2d_1" class="t s5_1">demonstrated CaP regression in men with metastatic disease after</div>
<div id="t2e_1" class="t s5_1">surgical castration and subsequent</div>
<div id="t2f_1" class="t s8_1">in vitro</div>
<div id="t2g_1" class="t s5_1">studies showed CaP cell</div>
<div id="t2h_1" class="t s5_1">growth after treatment with T, further supporting the CaP–androgen</div>
<div id="t2i_1" class="t s5_1">relationship.</div>
<div id="t2j_1" class="t v1_1 s7_1">8</div>
<div id="t2k_1" class="t s5_1">Despite these early ±ndings, there remains a dearth</div>
<div id="t2l_1" class="t s5_1">of clinical evidence supporting a link between high serum T and</div>
<div id="t2m_1" class="t s5_1">increased CaP risk. Thus, in the light of mounting evidence sug-</div>
<div id="t2n_1" class="t s5_1">gesting worse health outcomes in men diagnosed with hypogo-</div>
<div id="t2o_1" class="t s5_1">nadism, together with the lack of data supporting a clinical</div>
<div id="t2p_1" class="t s5_1">association between T and CaP growth, TRT has been initiated in</div>
<div id="t2q_1" class="t s5_1">hypogonadal men with CaP.</div>
<div id="t2r_1" class="t s5_1">Most studies examining hypogonadal men receiving TRT after</div>
<div id="t2s_1" class="t s5_1">radical prostatectomy (RP) have described no cases of biochemical</div>
<div id="t2t_1" class="t s5_1">recurrence or evidence of CaP progression in the setting of</div>
<div id="t2u_1" class="t s5_1">localized disease.</div>
<div id="t2v_1" class="t v1_1 s7_1">9–11</div>
<div id="t2w_1" class="t s5_1">Similarly, studies of patients with CaP treated</div>
<div id="t2x_1" class="t s5_1">with brachytherapy and/or external beam radiotherapy (EBRT) and</div>
<div id="t2y_1" class="t s5_1">on TRT have reported transient rises in prostate-speci±c antigen</div>
<div id="t2z_1" class="t s5_1">(PSA), but no patients with CaP recurrence or progression</div>
<div id="t30_1" class="t s5_1">prompting TRT cessation.</div>
<div id="t31_1" class="t v1_1 s7_1">12–14</div>
<div id="t32_1" class="t s5_1">Furthermore, no evidence of bone</div>
<div id="t33_1" class="t s5_1">metastasis or local recurrence has been observed in hypogonadal</div>
<div id="t34_1" class="t s5_1">patients with locally advanced CaP who underwent surgical</div>
<div id="t35_1" class="t s5_1">castration followed by intermittent TRT, nor have there been</div>
<div id="t36_1" class="t s5_1">signi±cant rises in PSA or evidence of CaP progression in patients</div>
<div id="t37_1" class="t s5_1">with CaP on active surveillance treated with TRT.</div>
<div id="t38_1" class="t v1_1 s7_1">15,16</div>
<div id="t39_1" class="t s5_1">In one study</div>
<div id="t3a_1" class="t s5_1">examining 96 men on TRT after RP, radiation therapy, or</div>
<div id="t3b_1" class="t s5_1">intermittent androgen deprivation, with 8 men demonstrating</div>
<div id="t3c_1" class="t s5_1">evidence of distant metastasis prior to TRT initiation, TRT was</div>
<div id="t3d_1" class="t s5_1">stopped in 60% of men due to rising PSA.</div>
<div id="t3e_1" class="t v1_1 s7_1">17</div>
<div id="t3f_1" class="t s5_1">The above small studies overall support the use of TRT in</div>
<div id="t3g_1" class="t s5_1">patients with CaP, irrespective of CaP treatment modality, in the</div>
<div id="t3h_1" class="t s5_1">setting of vigilant follow-up, as does a recent review of the pub-</div>
<div id="t3i_1" class="t s5_1">lished literature, particularly given the known effects of exogenous</div>
<div id="t3j_1" class="t s5_1">T on prostate cell growth</div>
<div id="t3k_1" class="t s8_1">in vitro</div>
<div id="t3l_1" class="t s5_1">.</div>
<div id="t3m_1" class="t v1_1 s7_1">18</div>
<div id="t3n_1" class="t s5_1">However, no published data</div>
<div id="t3o_1" class="t s5_1">from randomized controlled trials studying outcomes of TRT in</div>
<div id="t3p_1" class="t s5_1">treated CaP patients are currently available, and the data from</div>
<div id="t3q_1" class="t s5_1">retrospective studies are limited. In this retrospective study, we</div>
<div id="t3r_1" class="t s5_1">assess the ef±cacy and safety of TRT in a cohort of men with CaP</div>
<div id="t3s_1" class="t s5_1">treated with radiation, with the goal of adding to the literature</div>
<div id="t3t_1" class="t s5_1">describing TRT in men with CaP.</div>
<div id="t3u_1" class="t v1_1 s13_1">1</div>
<div id="t3v_1" class="t s14_1">Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA;</div>
<div id="t3w_1" class="t v1_1 s13_1">2</div>
<div id="t3x_1" class="t s14_1">Baylor College of Medicine, Houston, TX, USA and</div>
<div id="t3y_1" class="t v1_1 s13_1">3</div>
<div id="t3z_1" class="t s14_1">Methodist Urology Associates, The Methodist</div>
<div id="t40_1" class="t s14_1">Hospital, Houston, TX, USA. Correspondence: M Khera, Scott Department of Urology, Baylor College of Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030, USA.</div>
<div id="t41_1" class="t s14_1">E-mail: mkhera@bcm.edu</div>
<div id="t42_1" class="t v1_1 s13_1">4</div>
<div id="t43_1" class="t s14_1">These authors contributed equally to this work.</div>
<div id="t44_1" class="t s14_1">Received 23 January 2012; revised 5 June 2012; accepted 13 July 2012; published online 13 September 2012</div>
<div id="t45_1" class="t s15_1">International Journal of Impotence Research (2013) 25, 24–28</div>
<div id="t46_1" class="t s16_1">&amp;</div>
<div id="t47_1" class="t v2_1 s15_1">2013 Macmillan Publishers Limited</div>
<div id="t48_1" class="t v2_1 s15_1">All rights reserved 0955-9930/13</div>
<div id="t49_1" class="t s17_1">www.nature.com/ijir</div>

<form>
<input type="button"  tabindex="6"  id="form1_1" name="145 0 R"  pdfFieldName="145 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="3"  id="form1_2" name="142 0 R"  pdfFieldName="142 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="5"  id="form1_3" name="144 0 R"  pdfFieldName="144 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="2"  id="form1_4" name="141 0 R"  pdfFieldName="141 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="10"  id="form1_5" name="149 0 R"  pdfFieldName="149 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="11"  id="form1_6" name="150 0 R"  pdfFieldName="150 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="4"  id="form1_7" name="143 0 R"  pdfFieldName="143 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="7"  id="form1_8" name="146 0 R"  pdfFieldName="146 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="9"  id="form1_9" name="148 0 R"  pdfFieldName="148 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="8"  id="form1_10" name="147 0 R"  pdfFieldName="147 0 R" onclick="window.location.href='5.html';" style="cursor:pointer;"  title="Page 5" />
<input type="button"  tabindex="12"  id="form1_11" name="151 0 R"  pdfFieldName="151 0 R" onclick="window.location.href='mailto:mkhera@bcm.edu';" style="cursor:pointer;" title="mailto:mkhera@bcm.edu" />
<input type="button"  tabindex="13"  id="form1_12" name="152 0 R"  pdfFieldName="152 0 R" onclick="window.open('http://www.nature.com/IJIR','_blank');" style="cursor:pointer;" title="http://www.nature.com/IJIR" />
<input type="button"  tabindex="1"  id="form1_13" name="140 0 R"  pdfFieldName="140 0 R" onclick="window.open('http://dx.doi.org/10.1038/ijir.2012.29','_blank');" style="cursor:pointer;" title="http://dx.doi.org/10.1038/ijir.2012.29" />

</form>
<div id="pg1Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg1"><object width="909" height="1212" data="1/1.svg" type="image/svg+xml" id="pdf1" style="width:909px; height:1212px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!--[if lt IE 9]><script type="text/javascript">
var divCount = 154;
for (var i = 1; i < divCount; i++) {
    var div = document.getElementById("t" + i.toString(36) + "_1");
    if (div !== null) {
        div.style.top = (div.offsetTop * 4) + "px";
        div.style.left = (div.offsetLeft * 4) + "px";
        div.style.zoom = "25%";
    }
}
</script><![endif]-->

</div>
